Lanzhou

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease2 trials
• Stroke2 trials
• Chronic myeloid leukaemia1 trial
• Familial hypercholesterolaemia1 trial
• Multiple sclerosis1 trial
• Psoriasis1 trial

Phase

• Phase 34 trials
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Completed3 trials

Lead sponsor

• Novartis Pharmaceuticals6 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

  NCT04971226· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

  NCT04765657· Phase 3· Novartis Pharmaceuticals· Source

Closed trials

• Completed

  Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

  NCT05199571· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China

  NCT04894890· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source